OMEROS CORP — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Omeros reported Q2 2026 YARTEMLEA net revenue of $28.5M (up 190% from Q1's $9.9M). Management repurchased $30.5M of convertible 2029 Notes for $60.2M in July, reducing conversion shares from 11.4M to 6.5M and eliminating $8.6M in future interest. GAAP net income was $13.2M ($0.18/share) but included $11.5M mark-to-market gains on derivatives; adjusted net income was $1.8M ($0.02/share). Cash position: $132M at quarter-end. EMA rejected narsoplimab MAA in June but company requested re-examination. Pipeline includes Phase 2 OMS1029 (long-acting MASP-2), OMS527 addiction therapy (NIDA-funded), and OMS805 oncology candidate targeting Phase 1b in late 2027.
Why this rating
Commercial validation ($28.5M revenue is 17% of market cap) offsets EMA setback. Debt reduction materially improves dilution and cash runway. Pipeline progress is early-stage. Net positive but execution risk remains high.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.